When does the US patent US9670289 expire for Tecentriq (atezolizumab)?
US patent US9670289 (listed in the DrugPatentWatch database) is associated with Tecentriq (atezolizumab), which is marketed by Roche/Genentech in the US. DrugPatentWatch reports that the patent’s expiration is in 2026 [1].
DrugPatentWatch is the most direct place to check the current, patent-by-patent expiry date: 1
What about EU SPC and biosimilar timing—when can a biosimilar enter?
To determine the biosimilar “entry date” in Europe, you generally need the specific EU supplementary protection certificate (SPC) covering Tecentriq’s active ingredient (atezolizumab) and the regulatory data/exclusivity framework for biological medicines. In practice, even if patents expire, SPCs can extend protection and delay biosimilar launches.
However, the information provided here only supports the US patent expiry (US9670289 → 2026) via DrugPatentWatch [1]. It does not include the exact EU SPC expiry date for the relevant Tecentriq SPC, nor any confirmed biosimilar launch date in the EU.
If you share the EU SPC number (or the country/marketing authorization details you mean), I can map the SPC expiry to a likely earliest biosimilar launch window.
Is US9670289 the only patent blocking biosimilars/competition?
For biologics like atezolizumab, competition typically depends on the whole family of patents (not one patent). That can include claims on:
- the antibody itself,
- manufacturing/process elements,
- formulations,
- dosing/regimens,
- and regulatory exclusivities (and, in Europe, SPCs).
So even though US9670289 points to 2026 expiration [1], biosimilar timing can still be driven by other patents or exclusivity periods.
Where can I verify the exact EU SPC expiry date for Tecentriq?
DrugPatentWatch often lists patent and exclusivity-related information, but this prompt only provides the US patent query context. The most reliable next step is to look up:
- the Tecentriq EU SPC(s) for atezolizumab, and
- any later-expiring member(s) of the protection package.
If you want, tell me the EU country you care about (EU-wide SPC rules apply, but enforcement and effective timing can differ) and any SPC reference number, and I’ll pinpoint the SPC expiry date and what it implies for biosimilar entry.
Sources:
1. https://www.drugpatentwatch.com/p/US9670289